This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.

1. “PFIZER STRATEGIC
ANALYSIS”
DEVELOPED BY:
PHARM-NET

3. 8-May-17 3
INTRODUCTION

4. 8-May-17 3

5. STRATEGY
FORMULATION

6. 20-May-17 3
COMPANY MISSION AND
VISION STATEMENT

7. May 12, 2019 4
MISSION STATEMENT
EVALUATION MATRIX
ORGANIZATION CUSTOMERS
PRODUCTS
SERVICES
MARKETS GROWTH TECHNOLOGY
PFIZER YES NO YES NO NO
ORGANIZATION SELF-CONCEPT
CONCERN FOR
PUBLIC IMAGE
PHILOSOPHY CONCERN FOR
EMPLOYEES
PFIZER NO YES NO NO

8. May 12, 2019 4
ANALYSIS OF CURRENT MISSION
AND VISION STATEMENT
►The current vision statement of Pfizer answers what the
company wants to become.
►It is concise and well put together in a single sentence.
►On the other hand, the company’s mission statement does
not articulate three essential components of a mission
statement which are the company’s concern;
for employees, technology, and the concern for its survival,
growth, and profitability

9. May 12, 2019 4
RECOMMENDATION FOR
MISSION STATEMENT

10. May 12, 2019 5
SWOT ANALYSIS
STRENGTH
Strong brand image.
Profitable pharmaceutical company.
Strong sales force.
Safe and effective drugs.
Global presence in all over the countries.
WEAKNESS
Expiring patents.
Low spending in R&D as compared to other
competitors.
Heavy reliance on blockbuster drugs.
Discontinued Projects related to vaccines.
OPPORTUNITIES
Technology advancement
Opportunities in Emerging markets
Merger and acquisition of Wyeth and Park Davis
expanded market share and penetration.
More drugs for chronic diseases.
THREATS
Regulatory approval of drugs.
Tax rate on medicines.
Development of patent drugs by other companies.
New product development by competitors.

11. May 12, 2019 6
COMPETITIVE ANALYSIS

12. May 12, 2019 4
COMPETITIVE PROFILE MATRIX

13. May 12, 2019 4
COMPETITIVE PROFILE MATRIX
►The most important factor to being successful in the industry
is the Research and development as indicated by weight of
0.14.
►We can notice that Pfizer has the best market advertising,
customer service, store locations, financial profit and market
share but they were defeated in terms of research and
development which we note as the most important factor.
►Overall Pfizer is still the best among its competitors with a
score of 3.38 and Novartis as its strongest rival with 3.17
weighted score.

14. EXTERNAL FACTOR
EVALUATION

15. May 12, 2019 6
EXTERNAL FACTOR
EVALUATION (EFE) MATRIX

16. May 12, 2019 6
EXTERNAL FACTOR
EVALUATION (EFE) MATRIX

17. May 12, 2019 4
RESULTS OF EFE MATRIX
►The table illustrated above shows that Pfizer got a total
weighted score of 2.88 for its External Factor Evaluation (EFE)
matrix which shows an above average response to its existing
opportunities and threats in the industry.
►The current strategies that the company is using is
satisfactory, but these will need to be improved for Pfizer to keep
the top position among its competitors.

18. INTERNAL FACTOR
EVALUATION

19. May 12, 2019 6
INTERNAL FACTOR
EVALUATION (IFE) MATRIX

20. May 12, 2019 6
INTERNAL FACTOR
EVALUATION (IFE) MATRIX

21. May 12, 2019 4
RESULTS OF IFE MATRIX
►The table illustrated above shows that Pfizer
got a total weighted score of 3.06 for its
Internal Factor Evaluation matrix.
►This shows an above average response to its
existing Strengths and weaknesses inside the
company.
►Pfizer tries its best to capitalize on its
strengths and eliminate its weaknesses.

22. STRATEGY
SELECTION

23. SWOT
MATRIX

24. May 12, 2019 5
SWOT MATRIX
(STRENGTH)
(OPPORUNITY)
(OPPORUNITY)
(STRENGTH)
(STRENGTH)
(OPPORUNITY)

25. May 12, 2019 5
SWOT MATRIX
(STRENGTH)
(THREATS)
(STRENGTH)
(THREATS)
(STRENGTH) (THREATS)

26. May 12, 2019 5
SWOT MATRIX
(OPPORUNITY) (WEAKNESS)
(OPPORUNITY) (WEAKNESS)
)
(OPPORUNITY) (WEAKNESS)

27. May 12, 2019 5
SWOT MATRIX
(WEAKNESS) (THREATS)
(WEAKNESS)(THREATS)
(WEAKNESS)
(THREATS)

28. SPACE
MATRIX

29. SPACE MATRIX
May 12, 2019 6

30. SPACE MATRIX
May 12, 2019 6

31. SPACE MATRIX
May 12, 2019 6

32. IE
MATRIX

33. INTERNAL-EXTERNAL(IE) MATRIX
May 12, 2019 6
IFE-2.88
EFE:3.06
GROW AND BUILD
● Integration strategy
● Intensive strategy

34. RESULTS OF (IE)
MATRIX
May 12, 2019 6

35. GRAND
MATRIX

36. GRAND MATRIX
May 12, 2019 6

37. GRAND STRATEGY MATRIX
May 12, 2019 6

38. BCG
MATRIX

39. BCG MATRIX
May 12, 2019 6

40. BCG MATRIX
May 12, 2019 6
►It can be observed from this graph that Pharmaceutical products are the
stars of the company while its Animal Health and Corporate are its cash
cows.
►Pharmaceuticals, being the company’s star, has a large market share
and shows the greatest potential for growth among other divisions.
►The other segments, while having large market shares, show low levels
of growth.
►The pie slices within the circles also reveals the percent of corporate
profits contributed by each division.
►This shows that Pharmaceuticals contributed most profits, with Animal
Health in second.

41. QSPM
MATRIX

42. May 12, 2019 6
QUANTITATIVE STRATEGIC
PLANNING MATRIX (QSPM)

43. May 12, 2019 6
Key Factors
Increase
R&D funds
to increase
probability of
developing
new product
Market
Development
specifically on
Emerging
Markets
(China,India)
Acquisition
of Wyeth
Opportunities Weight AS TAS AS TAS AS TAS
1
Strategic agreements with other
pharmaceutical companies and orgs to
boost its research.
0.09 4 0.36 1 0.09 3 0.27
2
Increasing awareness about healthcare
needs
0.06 3 0.18 3 0.18 2 0.12
3
Global Penetration through mergers
and acquistions
0.07 3 0.21 2 0.14 4 0.28
4
Increasing demand for quality healthcare
solotions
0.07 2 0.14 3 0.21 3 0.21
5
Restructuring strategy designed to cut
costs and leaner company
0.03 3 0.09 3 0.09 4 0.12
6
Funding available to facilitate
product/company
0.02 4 0.08 3 0.06 4 0.08
7
Acquisitions (Wyeth) and in-licensing/
co-development opportunities
0.07 3 0.21 3 0.21 4 0.28
8 Expansion into biologies market 0.05 2 0.1 3 15 3 0.15
9 E-Commerce 0.03 2 0.06 2 0.06 2 0.06
10
High profits, revenues and funds are
available to uplift the company'sprogress
0.04 2 0.08 3 0.12 3 0.12

44. QSPM
May 12, 2019 6

45. QSPM
May 12, 2019 6

46. May 12, 2019 6

47. RESULTS ANALYSIS OF QSPM
May 12, 2019 6

48. STRATEGY
IMPLEMENTATION

49. May 12, 2019 6

50. May 12, 2019 6

51. May 12, 2019 6

52. STRATEGY
EVALUATION

53. May 12, 2019 6

54. May 12, 2019 6